[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Joe @Gantosj on x 13.3K followers
Created: 2025-07-08 19:56:29 UTC
$EPRX is using the "Cohort-8" dose based on the Safety Review Committee that conducted a comprehensive review of all safety, PK and efficacy data collected to date in all dose cohorts of the open label study including, importantly, the 4-week data from cohort X.
Based on this review, the Committee expressed confidence in the results from the safety and clinical efficacy outcomes of the cohort X dose and recommended its use as the first of the two active doses of the Ph-2b randomized, placebo-controlled portion of the study.
XXXXX engagements
